Table 3. Other immunomodulatory therapies used in patients with CS.

	WITH CS No. (Total n = 5,262)	Low-dose CS (n = 2,578) No (%)	CS Megadoses (n = 2,216) No (%)	P value
Use of lopinavir-ritonavir	3,082 (4,784)	1,499 (58.3)	1,583 (71.5)	<0.001
Use of hidroxychloroquine	4,284 (4,789)	2,260 (87.7)	2,024 (91.5)	<0.001
Use of beta-interferon 1B	669 (4,768)	376 (14.7)	293 (13.3)	0.17
Use of tocilizumab	842 (4,775)	325 (12.7)	517 (23.5)	<0.001
Use of anakinra	82 (4,751)	17 (0.7)	65 (3.0)	<0.001
Use of remdesivir	38 (4,755)	24 (0.9)	14 (0.6)	0.25
Use of chloroquine	213 (4,765)	79 (3.1)	134 (6.1)	<0.001
Use of immunoglobulins	53 (4,725)	12 (0.5)	41 (1.9)	<0.001
Use of baricitinib	86 (3,929)	15 (0.7)	71 (3.8)	<0.001
Use of colchicine	67 (4,732)	40 (1.6)	27 (1.2)	0.31
Use of inhaled beclomethasone	355 (4,746)	191 (7.5)	164 (7.5)	0.98

CS = Corticosteroids.